Cogent Biosciences, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Cogent Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $4.35M, a 86860.00% increase year-over-year.
- Cogent Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $5.76M, a 4132.35% increase year-over-year.
- Cogent Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.04M, a 1557.14% increase year-over-year.
- Cogent Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $5.00K, a 95.41% decline year-over-year.
- Cogent Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $11.55M, a 5702.01% increase from fiscal 2024.
- Cogent Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $199.00K, a 79.38% decline from fiscal 2023.
- Cogent Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $965.00K, a 22.05% decline from fiscal 2022.
- Cogent Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $1.24M, a 5058.33% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $4.35M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $5.76M 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $11.55M 10-K · filed 2026-02-17 | |
| 2025-09-30 | $1.04M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $5.00K 10-Q · filed 2026-08-10 | |
| 2025-03-31 | $136.00K 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $199.00K 10-K · filed 2026-02-17 | |
| 2024-09-30 | $63.00K 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $109.00K 10-Q · filed 2025-11-07 | |
| 2024-03-31 | $356.00K 10-Q · filed 2024-11-12 | |
| 2023-12-31 | $965.00K 10-K · filed 2026-02-17 | |
| 2023-09-30 | $731.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $102.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $132.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $1.24M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $914.00K 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $9.00K 10-Q · filed 2022-11-14 | |
| 2021-12-31 | $24.00K 10-K · filed 2024-02-26 | |
| 2021-09-30 | $24.00K 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $512.00K 10-K · filed 2022-03-15 | |
| 2020-09-30 | $335.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $62.00K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $38.00K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $108.00K 10-K · filed 2021-03-16 | |
| 2019-06-30 | $97.00K 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $11.00K 10-Q · filed 2020-11-09 | |
| 2018-12-31 | $609.00K 10-K · filed 2020-03-26 | |
| 2018-09-30 | $175.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $11.00K 10-Q · filed 2019-11-12 | |
| 2018-03-31 | $28.00K 10-Q · filed 2019-11-12 | |
| 2017-12-31 | $60.00K 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |